NEWS
MHRA appoints first Chief Medical and Scientific Officer
Professor Jacob George has been appointed as the first Chief Medical and Scientific Officer for the Medicines and Healthcare products Regulatory Agency (MHRA). This is a pivotal role that will drive scientific excellence and shape the future of regulation through the MHRA science strategy. Professor George is currently Professor of
Cardiovascular Medicine and Therapeutics at the University of Dundee Medical School, and consultant physician and clinical lead for the Cardiovascular Risk service in NHS Tayside. He is qualified
ProImmune expands into new headquarters
Life science reagents company ProImmune has opened its new global headquarters building at Oasis Park, Oxford, enabling significant expansion of its operations and capacity to serve its global client base. Located within Oxford’s renowned bioscience and innovation ecosystem, the 70,000 sq ft Oasis Park is already home to six existing tenants. ProImmune’s new 18,000 sq ft main headquarters represents a substantial investment in state-of-the-art laboratories, providing ProImmune with the space and infrastructure to accelerate innovation in the REVEAL Immunogenicity System, its suite of assay services to help understand immune responses to vaccines and therapeutic products, and the expansion of the company’s revolutionary Ankyron target binding reagent platform. Ankyrons are small, recombinant, target binding ankyrin repeat proteins, developed by ProImmune to overcome challenges in in antibody research. “Our
new global headquarters at Oasis Park, Oxford, are a
reflection of ProImmune’s commitment to scientific excellence in immunology and global one-health biology,” said Dr Nikolai Schwabe, Chief Executive Officer of ProImmune.
WWW.PATHOLOGYINPRACTICE.COM DECEMBER 2025 11
in Clinical Pharmacology and General Internal Medicine and is an accredited European Hypertension Specialist. Professor Jacob George commented: “I’m delighted to be joining the MHRA at an important time for the agency and the UK life sciences sector. The MHRA has a direct influence on the safety and effectiveness of the medicines, vaccines, and health technologies used every day by millions of people across the UK, and I’m looking
forward to working with colleagues to make a major contribution to high quality patient care and life sciences innovation.” Prof George has extensive UK and
international experience and is a Fellow of the Royal College of Physicians Edinburgh, European Society of Cardiology and the British Hypertension Society, as well as visiting Professor at the Dnipro State Medical University, Ukraine. He is an alumnus of the Universities of Sheffield and Dundee. Professor George will join the MHRA on 5 January 2026 and will work from the MHRA’s London office and its science campus in Hertfordshire,
while retaining his home base in Scotland, supporting the MHRA’s strong commitment to being a visible regulator in all four nations.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60
